How to Get Zepbound Online (Tirzepatide) in 2026
Zepbound is Eli Lilly's FDA-approved tirzepatide injection for chronic weight management. Brand-name Zepbound is now available through telehealth in pen and KwikPen formats.
Zepbound contains tirzepatide, a dual GIP and GLP-1 receptor agonist FDA-approved in November 2023 for chronic weight management in adults with obesity or overweight with comorbidities.
Adults seeking medically supervised weight loss who meet BMI criteria, particularly those who have plateaued on semaglutide or want a dual-receptor approach.
Pen and KwikPen formats are available. Monthly cost without insurance typically ranges from $1,000 to $1,300.
Rankings combine clinical formulary depth, pricing transparency, and shipping reliability — weighted equally and reviewed quarterly. Read the full methodology →
Providers That Prescribe Zepbound
Mainstream telehealth giant with FDA-approved GLP-1s, an insurance concierge, and prepay savings.
Flat-rate compounded GLP-1s plus brand-name Wegovy and Zepbound, with all dosages priced the same.
Board-certified primary-care telehealth with the widest brand-name GLP-1 access in this list.
Full-spectrum GLP-1 program with both compounded and brand-name access plus unlimited provider check-ins.
Flat upfront pricing with the same dose-equal cost across both compounded and brand-name GLP-1s.
Publicly traded telehealth giant with weight-loss, ED, and hair-loss programs under one roof.
Women-focused sister brand to Hims spanning GLP-1, hair, skincare, and menopause care.
Weight-loss program designed specifically for time-crunched men.
Cash-pay telehealth marketplace with transparent per-visit pricing and Costco-member discounts.
Doctor-guided GLP-1 program with both injectable and tablet options across multiple categories.
Clinician-guided GLP-1 platform with both compounded and brand-name access plus overnight shipping.
Sermorelin-led peptide clinic that also covers GLP-1, NAD+, and brand-name Zepbound.
Wide compounded and brand-name catalog covering weight loss, anti-aging, and hair growth without insurance.
Personalised GLP-1 and sexual-wellness program with insurance navigation and optional nutrition coaching.
GLP-1 platform that pairs medication with one-on-one coaching and a broad off-label formulary.
GLP-1 clinic offering injections, oral semaglutide, drops, and lozenges plus brand-name Wegovy and Zepbound.
Legacy WW lifestyle program paired with brand-name GLP-1 prescriptions and clinician oversight.
GLP-1 weight-loss platform combined with personalised nutrition and fitness coaching.
What the Studies Actually Show
Zepbound is FDA-approved tirzepatide for chronic weight management. The evidence below comes from the SURMOUNT trials (which led to the 2023 obesity approval) and the SURMOUNT-OSA trial (which led to the 2024 OSA-in-obesity approval).
| Endpoint | Finding |
|---|---|
| Mean weight loss (SURMOUNT-1, 72 weeks, 15 mg)1 | −20.9% body weight vs −3.1% placebo in adults with obesity without diabetes |
| Mean weight loss with T2D (SURMOUNT-2, 72 weeks, 15 mg)2 | −14.7% body weight in adults with type 2 diabetes |
| Sleep apnea (SURMOUNT-OSA)3 | Tirzepatide reduced apnea-hypopnea index (AHI) by ~25–29 events/hour vs placebo at 52 weeks; FDA-approved labeling for moderate-to-severe OSA in obesity |
| GI side effects (FDA prescribing information)4 | Nausea ≥10%, diarrhea ≥10%, vomiting ≥5%, constipation ≥5% |
| Boxed warning4 | Risk of thyroid C-cell tumors observed in rodent studies; contraindicated in personal/family history of MTC or MEN 2 |
| A1C reduction (T2D, SURPASS program)5 | ≈1.9–2.4% A1C reduction at 15 mg weekly across SURPASS-1 through SURPASS-5 |
| Compounded tirzepatide — evidence basis6 | Active ingredient is identical to Zepbound/Mounjaro; efficacy is inferred from the active ingredient. FDA does not formally approve compounded products |
Frequently Asked Questions
What is the difference between Zepbound and Mounjaro?
Both contain tirzepatide. Mounjaro is FDA-approved for type 2 diabetes; Zepbound is FDA-approved for chronic weight management. The active ingredient and dosing are otherwise identical.
- SURMOUNT-1 — NEJM 2022 · Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205–216.
- SURMOUNT-2 — Lancet 2023 · Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023;402(10402):613–626.
- SURMOUNT-OSA — NEJM 2024 · Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med 2024;391:1193–1205.
- FDA Prescribing Information — Zepbound (tirzepatide) · ZEPBOUND (tirzepatide) injection, for subcutaneous use. U.S. Food and Drug Administration prescribing information.
- SURPASS — program summary · Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med 2021;385:503–515.
- FDA — Compounding and the FDA: Questions and Answers · U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers (last updated 2024).
RxNotebook is an editorial publication. Citations point to peer-reviewed journals, FDA labeling, and clinical society guidelines. We are not affiliated with the studies cited above. This page is for general information and is not medical advice.